A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1291 participants.
Also called NCT05352815
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,291 participants
- Sponsor
- Registry
-
NCT05352815 -
2020-005281-34
-
- Other papers using this trial's data
- Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Bulgaria, China, Croatia, Finland, India, Italy, Japan, Mexico, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, South Africa, South Korea, Taiwan, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT05352815. Randomized; no masking; primary purpose treatment. Start 2022-06-01 (actual); primary completion 2024-03-19 (actual). Results posted on 2025-04-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
- Acronym
- COMBINE 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- IcoSema
- Intervention (Drug)
- Insulin icodec
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05352815- Content hash
aadefcdc26b5e98c87c892b05aa0b6f0dd1bf72ce776b7ee495f1a0024630794